Welcome to your daily round-up of everything happening in the world of neurorehabilitation.
Research news
Cold brain cell molecules reveal how epilepsy drug works
By super cooling a molecule on the surface of brain cells down to about minus 180 degrees Celsius — nearly twice as cold as the coldest places in Antarctica — scientists at Johns Hopkins Medicine say they have determined how a widely-used epilepsy drug works to dampen the excitability of brain cells and help to control, although not cure, seizures.
Severe paediatric neurological manifestations with SARS-CoV-2
A new study has suggested that children and adolescents with acute SARS-CoV-2 or multisystem inflammatory syndrome in children (MIS-C) and severe neurological manifestations may be at high risk for long-term impairment and may benefit from screening and early intervention to assist recovery.
How the brain is affected by Huntington’s Disease
The genetic disease Huntington’s not only affects nerve cells in the brain but also has widespread effects on microscopic blood vessels according to research. These changes to the vasculature were also observed in the pre-symptomatic stages of the disease, demonstrating the potential for this research for predicting brain health and evaluating the beneficial effects of lifestyle changes or treatments.
Company and financial neuro-rehab news
Product candidates for neuroinflammation imaging and treatment
Ashvattha Therapeutics, a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, has announced the presentation of data demonstrating the therapeutic potential of Ashvattha’s novel CSF1R dendranib for MS based on symptom reduction in a mouse experimental autoimmune encephalitis (EAE) model. This therapeutic effect was further evidenced by a reduction in neuroinflammation by PET imaging using Ashvattha’s proprietary ¹⁸F-OP-801 radiotracer.
Blood-Brain barrier technology platform
Alector Inc., a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host a virtual event to discuss Alector Brain Carrier, a proprietary, versatile blood-brain barrier (BBB) technology platform that is being applied selectively to the Company’s next-generation product candidates and research pipeline. Crossing the Blood-Brain Barrier: Advancing the Next Generation of Alector Neurodegenerative Therapies will take place on June 18, 2024, from 3:00 pm – 4:30 pm Eastern Daylight Time (EDT).
Technology news
Football most common cause of concussion
The World Economic Forum (WEF) has selected 10 Indian tech startups under its 2024 Technology Pioneers initiative, focused on applying new breakthroughs in AI to develop clean energy solutions, healthcare innovation and progress in biotech, space and neurotechnology.
